Applications

1722 – Axicabtagene ciloleucel (Yescarta®) for relapsed or refractory large B-cell lymphoma

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Closed
  • Outcome Not supported

Application details

Reason for application

Highly Specialised Therapy – National Health Reform Agreement

Service or technology in this application

Axicabtagene ciloleucel is a CAR T-cell product produced using a patient’s own T-cells, making the product unique to each patient. A patient’s T-cells are collected via a process called leukapheresis. The T-cells are genetically modified in a lab to express an anti-CD19 chimeric antigen receptor (CAR) which targets the lymphoma B-cells. Following modification and subsequent proliferation, the T-cells are infused back into the patient where they target and kill the lymphoma B-cells.

Type: Therapeutic technology

Medical condition this application addresses

Large B-cell lymphoma (LBCL) is a collection of entities that are subtypes of non-Hodgkin’s lymphoma. LBCL accounts for roughly one third of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy, extranodal disease or both.

Consultation survey and deadlines

  • PASC consultation: Expedited – bypassing PASC
  • MSAC consultation: Closed Friday 10 February 2023

Meetings to consider this application

  • PASC meeting: Bypassing PASC
  • ESC meeting: 9–10 February 2023
  • MSAC meeting: 30–31 March 2023